Perakizumab, being studied by Novan, represents a exciting breakthrough in the management against multiple scarring diseases. Distinct from traditional therapies, this agent carefully targets and inhibits transforming https://zaynabssix187931.mpeblog.com/74430010/perakizumab-a-new-hope-for-fibrotic-disease